☆ 4.7 Editorial Material

Harnessing Innate Immunity to Suppress Lymphoma

JOURNAL OF CLINICAL ONCOLOGY (2010)

期刊

JOURNAL OF CLINICAL ONCOLOGY

卷 28, 期 28, 页码 4295-4296

出版社

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2010.30.4212

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Chemistry, Multidisciplinary

Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy

DaeYong Lee, Kristin Huntoon, Yifan Wang, Wen Jiang, Betty Y. S. Kim

Summary: The discovery of immune checkpoint blockade has revolutionized cancer treatment, but current immunotherapies are only effective for a small subset of patients. Future advancements in cancer immunotherapy will focus on developing novel therapeutic molecules or immunoengineered cells. Biomaterials can efficiently reprogram and recruit immune cells in tumors to activate T cell immunity against advanced cancers.

ADVANCED MATERIALS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Zika virus alters centrosome organization to suppress the innate immune response

Andrew Kodani, Kristeene A. Knopp, Elizabeth Di Lullo, Hanna Retallack, Arnold R. Kriegstein, Joseph L. DeRisi, Jeremy F. Reiter

Summary: ZIKV infection disrupts centrosome organization and affects the localization and stability of centrosomal proteins, as well as the function of regulators of the innate immune response, thereby tempering the immune response.

EMBO REPORTS (2022)

添加到收藏夹

Review Microbiology

Harnessing the Immune Response to Fungal Pathogens for Vaccine Development

Amariliz Rivera, Jennifer Lodge, Chaoyang Xue

Summary: Invasive fungal infections are emerging diseases that cause over 1.5 million deaths annually worldwide. Despite the lack of currently available fungal vaccines, there has been growing interest in this field, with one Candida vaccine completing phase 2 clinical trials.

ANNUAL REVIEW OF MICROBIOLOGY (2022)

添加到收藏夹

Review Immunology

Chronovaccination: Harnessing circadian rhythms to optimize immunisation strategies

Claire O. Otasowie, Rachel Tanner, David W. Ray, Jonathan M. Austyn, Brendon J. Coventry

Summary: As a public health measure, vaccination provides effective protection against infectious diseases. Recent studies have shown that the timing of vaccination can play a critical role in its efficacy due to the influence of circadian rhythms on immune responses. This review explores the potential of chronovaccination as a strategy for optimizing immunization.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Immunology

Harnessing Mechanisms of Immune Tolerance to Improve Outcomes in Solid Organ Transplantation: A Review

Priscila Ferreira Slepicka, Mahboubeh Yazdanifar, Alice Bertaina

Summary: This article discusses the conventional and unconventional immunological mechanisms underlying the development of immune tolerance in solid organ transplant (SOT) recipients, as well as how these mechanisms can inform clinical progress. Specifically, recent mechanistic studies elucidating the role of regulatory cells in dampening cytotoxic immune reactivity and fostering a tolerogenic environment are reviewed. The understanding of regulatory cells can shape graft engineering and other therapeutic strategies to improve long-term outcomes for patients receiving hematopoietic stem cell transplantation (HSCT) and SOT.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

T6SS translocates a micropeptide to suppress STING-mediated innate immunity by

Lingfang Zhu, Lei Xu, Chenguang Wang, Changfu Li, Mengyuan Li, Qinmeng Liu, Xiao Wang, Wenhui Yang, Damin Pan, Lingfei Hu, Yadong Yang, Zhiqiang Lu, Yao Wang, Dongsheng Zhou, Zhengfan Jiang, Xihui Shen

Summary: This study reveals a unique virulence strategy of Yersinia pseudotuberculosis (Yptb) involving modulating the availability of the immunostimulatory metal ion Mn2+ in host cells. The Yptb T6SS delivers a micropeptide TssS into host cells to enhance virulence, but mutant strains lacking TssS show reduced virulence and stronger host innate immune responses. Furthermore, TssS functions as a Mn2+-chelating protein and inhibits the STING-mediated immune response by sequestering Mn2+, leading to bacterial immune evasion and sabotaged bacterial clearance in vivo.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Development of VHL-recruiting STING PROTACs that suppress innate immunity

Zhichuan Zhu, Rebecca L. Johnson, Zhigang Zhang, Laura E. Herring, Guochun Jiang, Blossom Damania, Lindsey I. James, Pengda Liu

Summary: This study reports a series of STING-agonist derived PROTACs that promote STING degradation in renal cell carcinoma cells. It demonstrates that these STING PROTACs activate STING and target activated/phospho-STING for degradation. Additionally, the study reveals the role of VHL as a bona fide E3 ligase for STING in RCC and the promotion of VHL-dependent STING degradation by VHL-recruiting STING PROTACs.

CELLULAR AND MOLECULAR LIFE SCIENCES (2023)

添加到收藏夹

Article Cell Biology

Harnessing Innate Immunity to Treat Mycobacterium tuberculosis Infections: Heat-Killed Caulobacter crescentus as a Novel Biotherapeutic

Nancy Gupta, Satish Vedi, Saurabh Garg, Eric Loo, Jie Li, Dennis Y. Kunimoto, Rakesh Kumar, Babita Agrawal

Summary: Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is a serious infectious disease. This study explored the use of a heat-killed non-pathogenic microbe, Caulobacter crescentus (HKCC), to induce innate immunity and limit Mtb infection. The combination of HKCC and a first-line drug isoniazid showed significant reduction in Mtb infection in mice, suggesting a potential new therapeutic strategy for tuberculosis in humans.

CELLS (2023)

添加到收藏夹

Article Oncology

PPAR & gamma; activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression

Melissa Prat, Kimberley Coulson, Clement Blot, Godefroy Jacquemin, Mathilde Romano, Marie-Laure Renoud, Mohamad AlaEddine, Augustin Le Naour, Helene Authier, Mouna Chirine Rahabi, Khaddouj Benmoussa, Marie Salon, Melissa Parny, Jean-Pierre Delord, Gwenael Ferron, Lise Lefevre, Bettina Couderc, Agnes Coste

Summary: In this study, it was found that activation of PPARγ in treated small peritoneal macrophages can inhibit ovarian adenocarcinoma growth, regulate the proportion of immune cells, and attenuate the immunosuppressive properties of tumor-associated macrophages.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Group 2 innate lymphoid cells suppress the pathology of neuromyelitis optica spectrum disorder

Ying Kong, Han-Dong Li, Dan Wang, Xiaolin Gao, Chunsheng Yang, Minshu Li, Ting Chang, Qiang Liu

Summary: The study found a correlation between the reduction of ILC2 and disease severity in neuromyelitis optica spectrum disorder (NMOSD), and expanding ILC2 could alleviate the pathological conditions.

FASEB JOURNAL (2021)

添加到收藏夹

Review Oncology

The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity

Stavros P. Papadakos, Nikolaos Dedes, Elias Kouroumalis, Stamatios Theocharis

Summary: This article explores the impact of the NLRP3 inflammasome on hepatocellular carcinoma (HCC) and presents a hypothesis about its potential role. Hepatotropic viruses avoid the NLRP3 inflammasome to sustain chronic infection leading to cirrhosis, while the activation of NLRP3 promotes pro-tumorigenic effects in established tumors. Therefore, studying the role of the NLRP3 inflammasome in HCC is of great importance in identifying new therapeutic targets.

CANCERS (2022)

添加到收藏夹

Article Virology

Harnessing the Genetic Plasticity of Porcine Circovirus Type 2 to Target Suicidal Replication

Agm Rakibuzzaman, Pablo Pineyro, Angela Pillatzki, Sheela Ramamoorthy

Summary: The study showed that vaccination with the suicidal PCV2 vaccine constructs induced strong virus-neutralizing antibody responses, preventing lesions, body-weight loss, and viral replication. The construct was not detectable in vaccinated pigs' sera 14 days post-vaccination, indicating high safety. Exposure to immune selection pressure resulted in mutations to a stop signal, demonstrating both effectiveness and safety in rapidly attenuating PCV2.

VIRUSES-BASEL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

GABAergic synapses suppress intestinal innate immunity via insulin signaling in Caenorhabditis elegans

Zhongfan Zheng, Xiumei Zhang, Junqiang Liu, Ping He, Shan Zhang, Yongning Zhang, Jie Gao, Shengmei Yang, Na Kang, Muhammad Irfan Afridi, Shangbang Gao, Chunhong Chen, Haijun Tu

Summary: The study demonstrates that GABAergic neurotransmission is crucial in regulating the resistance of nematodes to pathogens and is associated with the modulation of intestinal immunity.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Article Microbiology

Harnessing the plant microbiome to promote the growth of agricultural crops

Janie Zhang, Jamie Cook, Jacob T. Nearing, Junzeng Zhang, Renee Raudonis, Bernard R. Glick, Morgan G. I. Langille, Zhenyu Cheng

Summary: The rhizosphere microbiome consists of various microorganisms that interact with crop plants, potentially influencing plant growth. Studying the rhizosphere microbiome has the potential to increase crop yield and quality to meet the growing demand for food.

MICROBIOLOGICAL RESEARCH (2021)

添加到收藏夹

Review Immunology

How to Train Your Dragon: Harnessing Gamma Delta T Cells Antiviral Functions and Trained Immunity in a Pandemic Era

Jonathan Caron, Laura Alice Ridgley, Mark Bodman-Smith

Summary: Emerging evidence suggests that gamma delta T cells play a crucial role in the immune response to viral infections by detecting viruses early and triggering antiviral functions. Activating the antiviral potential of gamma delta T cells could be harnessed to prevent or treat viral infections effectively.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis

James J. Clark, Dominic Dwyer, Nina Pinwill, Peter Clark, Peter Johnson, Allan Hackshaw

Summary: The COVID-19 pandemic led to a reduction in systemic anticancer treatment registrations in England, but numbers began to increase after the introduction of treatment options to reduce patient risk. More assessment is needed for the outcomes of providing less or delayed treatments, especially for advanced cancers and neoadjuvant therapies.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial

James Russell, Angela Collins, Alexis Fowler, Mamatha Karanth, Chandan Saha, Suzanne Docherty, Joseph Padayatty, Kyaw Maw, Isabel Lentell, Lisa Cooke, Andrew Hodson, Nimish Shah, Shalal Sadullah, Nicholas Grigoropoulos, Wendi Qian, Amy A. Kirkwood, Benjamin J. Uttenthal, Peter Johnson, George A. Follows

Summary: For advanced-stage classical Hodgkin lymphoma, treatment with ABVD or escalated BEACOPP remains the international standard of care. Real-world ABVD patients showed similar survival rates compared to trial patients, while real-world eBEACOPP patients had superior progression-free survival. Higher-risk patients may benefit disproportionately from more intensive therapy.

ANNALS OF HEMATOLOGY (2021)

添加到收藏夹

Article Hematology

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

James Heward, Lola Konali, Annalisa D'Avola, Karina Close, Alison Yeomans, Martin Philpott, James Dunford, Tahrima Rahim, Ahad F. Al Seraihi, Jun Wang, Koorosh Korfi, Shamzah Araf, Sameena Iqbal, Findlay Bewicke-Copley, Emil Kumar, Darko Barisic, Maria Calaminici, Andrew Clear, John Gribben, Peter Johnson, Richard Neve, Pedro Cutillas, Jessica Okosun, Udo Oppermann, Ari Melnick, Graham Packham, Jude Fitzgibbon

Summary: Loss-of-function mutations in KMT2D are a key feature of germinal center lymphomas, but inhibiting the KDM5 family can restore H3K4 methylation levels, reactivate repressed gene expression, and alter B-cell signaling.

BLOOD (2021)

添加到收藏夹

Article Hematology

Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib

Sriram Balasubramanian, Songbai Wang, Christopher Major, Brendan Hodkinson, Michael Schaffer, Laurie H. Sehn, Peter Johnson, Pier Luigi Zinzani, Jodi Carey, S. Martin Shreeve, Steven Sun, John Gerecitano, Jessica Vermeulen, Louis M. Staudt, Wyndham Wilson

Summary: In the phase III PHOENIX trial, concordance between immunohistochemistry (IHC) and gene expression profiling (GEP) for determining diffuse large B-cell lymphoma (DLBCL) cell of origin (COO) was assessed. The study found high concordance between IHC and GEP in determining non-GCB DLBCL, with consistent survival outcomes. Centralized IHC may be used to enrich populations for response to ibrutinib plus R-CHOP.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Moving the goalposts while scoring-the dilemma posed by new PET technologies

Julian M. M. Rogasch, Ronald Boellaard, Lucy Pike, Peter Borchmann, Peter Johnson, Jurgen Wolf, Sally F. Barrington, Carsten Kobe

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Review Oncology

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs

Jemma Longley, Peter W. M. Johnson

Summary: Epigenetic modifier gene mutations are common in patients with follicular lymphoma, and they are targeted by drugs like EZH2 inhibitors. Clinical trials have shown promising results in treating patients with these mutations, as well as in wild-type disease due to off target effects. Further studies with molecular profiling are needed for better understanding of how these mutations evolve over time.

CURRENT ONCOLOGY REPORTS (2021)

添加到收藏夹

Article Optics

Superresolved polarization-enhanced second-harmonic generation for direct imaging of nanoscale changes in collagen architecture

Peter Johnson, Artemis Karvounis, H. Johnson Singh, Christopher J. Brereton, Konstantinos Bourdakos, Kerry Lunn, James J. W. Roberts, Donna E. Davies, Otto L. Muskens, Mark G. Jones, Sumeet Mahajan

Summary: The study utilizes photonic nanojet phenomenon to achieve super-resolution second-harmonic generation (SR-SHG) imaging, improving resolution by approximately 2.3 times compared to traditional methods. This technique allows observation of changes in SHG-active structures such as collagen at the nanoscale, offering a potential new tool for biological research and drug discovery.

OPTICA (2021)

添加到收藏夹

Article Hematology

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

Giorgia Chiodin, Samantha Drennan, Enrica A. Martino, Laura Ondrisova, Isla Henderson, Luis del Rio, Ian Tracy, Annalisa D'Avola, Helen Parker, Silvia Bonfiglio, Lydia Scarfo, Lesley-Ann Sutton, Jonathan C. Strefford, Jade Forster, Oliver Brake, Kathleen N. Potter, Benjamin Sale, Stuart Lanham, Marek Mraz, Paolo Ghia, Freda K. Stevenson, Francesco Forconi

Summary: Chronic lymphocytic leukemia (CLL) cells with high surface IgM (sIgM) levels progress more rapidly and can regain sIgM expression during ibrutinib therapy. High sIgM levels are associated with shorter time to new treatment. Ibrutinib inhibits sIgM-mediated signaling more effectively in CLL cells with low sIgM levels.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Cell Biology

BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells

Rachael Arthur, Alexander Wathen, A. Elizabeth Lemm, K. Freda Stevenson, Francesco Forconi, J. Adam Linley, J. Andrew Steele, Graham Packham, Beatriz Valle-Argos

Summary: BTK inhibitors (BTKi) have shown significant improvement in the treatment of chronic lymphocytic leukemia (CLL) and certain forms of B-cell lymphoma. However, the activation of BTK-independent calcium signaling may limit the efficacy of BTKi. Inhibition of SYK or dual inhibition of BTK and RAC may be alternative strategies to enhance pathway blockade.

CELLULAR SIGNALLING (2022)

添加到收藏夹

Article Oncology

Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial

Richard D. Neal, Peter Johnson, Christina A. Clarke, Stephanie A. Hamilton, Nan Zhang, Harpal Kumar, Charles Swanton, Peter Sasieni

Summary: NHS-Galleri is a trial that aims to assess the effectiveness of a blood test in early cancer detection. It has enrolled over 140,000 participants from England and will determine the clinical utility of population screening with the test.

CANCERS (2022)

添加到收藏夹

Article Hematology

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial

Peter W. M. Johnson, Sriram Balasubramanian, Brendan Hodkinson, S. Martin Shreeve, Steven Sun, Srimathi Srinivasan, Andrew J. Steele, Jessica Vermeulen, Laurie H. Sehn, Wyndham H. Wilson

Summary: High BCL2/MYC coexpression in DLBCL may indicate a subset of non-GCB DLBCL that is sensitive to ibrutinib, leading to improved event-free survival (EFS) in patients aged <60 years. This study also identified an association between high BCL2/MYC coexpression and activated B-cell-like and MYD88(L265P)/CD79B-mutated subtypes of DLBCL. Further investigation is warranted to explore the potential therapeutic implications of targeting the B-cell receptor (BCR) pathway in this subset of DLBCL patients.

BLOOD ADVANCES (2023)

添加到收藏夹

Article Oncology

Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL

Dean Bryant, Lindsay Smith, Karly Rai Rogers-Broadway, Laura Karydis, Jeongmin Woo, Matthew D. Blunt, Francesco Forconi, Freda K. Stevenson, Christopher Goodnow, Amanda Russell, Peter Humburg, Graham Packham, Andrew J. Steele, Jonathan C. Strefford

Summary: Chronic lymphocytic leukaemia (CLL) cells can express unmutated (U-CLL) or mutated (M-CLL) immunoglobulin heavy chain (IGHV) genes, with differences in clinical behaviors, B cell receptor (BCR) signaling capacity, and transcriptional profiles. Through mRNA/miRNA sequencing of 38 CLL cases, researchers identified differentially expressed mRNAs and miRNAs between U-CLL and M-CLL, as well as potential regulatory roles of the 14q32 miRNA locus in CLL-related gene regulation and BCR signaling.

LEUKEMIA (2023)

添加到收藏夹

Article Oncology

XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression

Jack G. Fisher, Amber D. P. Doyle, Lara V. Graham, Shreyanshi Sonar, Ben Sale, Isla Henderson, Luis Del Rio, Peter W. M. Johnson, Yosef Landesman, Mark S. Cragg, Francesco Forconi, Christopher J. Walker, Salim. I. Khakoo, Matthew D. Blunt

Summary: The XPO1 inhibitor selinexor is being investigated in combination with the BTK inhibitor ibrutinib for CLL and non-Hodgkin lymphoma. Selinexor induces apoptosis of tumor cells and modulates NK cell and T cell cytotoxicity against lymphoma cells.

LEUKEMIA (2023)

添加到收藏夹

Article Immunology

KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity

Matthew D. Blunt, Andres Vallejo Pulido, Jack G. Fisher, Lara Graham, Amber D. P. Doyle, Rebecca Fulton, Matthew J. Carter, Marta Polak, Peter W. M. Johnson, Mark S. Cragg, Francesco Forconi, Salim Khakoo

Summary: This study demonstrates that KIR2DS2 marks a population of NK cells primed for anticancer activity and is associated with enhanced NK cell-mediated cytotoxicity.

JOURNAL OF IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study

Sean H. Lim, Beth Stuart, Debora Joseph-Pietras, Marina Johnson, Nicola Campbell, Adam Kelly, Danielle Jeffrey, Anna H. Turaj, Kate Rolfvondenbaumen, Celine Galloway, Thomas Wynn, Adam R. Coleman, Benjamin Ward, Karen Long, Helen Coleman, Carina Mundy, Andrew T. Bates, Diana Ayres, Robert Lown, Janlyn Falconer, Oliver Brake, James Batchelor, Victoria Willimott, Anna Bowzyk Al-Naeeb, Lisa Robinson, Ann O'Callaghan, Graham P. Collins, Tobias Menne, Saul N. Faust, Christopher P. Fox, Matthew Ahearne, Peter W. M. Johnson, Andrew J. Davies, David Goldblatt

Summary: Patients with hematological malignancies, especially those undergoing active anticancer treatment or on anti-CD20 therapy, show compromised immune responses to COVID-19 vaccination. However, booster vaccination can significantly improve antibody responses in indolent B-cell lymphoma patients, and antigen-specific T-cell responses are observed in the majority of patients after a third dose, regardless of their cancer treatment status.

NATURE CANCER (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.